NCT07035886 A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea
| NCT ID | NCT07035886 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Takeda |
| Condition | Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2025-09-29 |
| Primary Completion | 2029-09-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib as per the approved indications.
Eligibility Criteria
Inclusion Criteria: * Age greater than or equal to (\>=)18 years. * Participants who are initiate treatment or will be treated with Fruzaqla according to the approved label of South Korea. * Participant voluntarily consent to participate in the study. Exclusion criteria: * Participants for whom Fruzaqla is contraindicated or those with risks that should avoid starting Fruzaqla, as per the product label. * Participants actively participating in other interventional clinical trial(s) on mCRC treatments. * Pregnant or breastfeeding women.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.